Very interesting CC; I think management has learned immensely from the previous CC's. The focus is heavily geared towards Galaxy 2 success; if if the results are strong after the interim analysis...they can file for expedited FDA approval as long as the DMC supports the decision (mid 2015).
I think the one main concern was to shut down the Enchant trial which had a $2.4 mm budget for the new focus on the I Spy2 trial; but it was because they are steering away from the Monotherapy oriented trial for a smaller opportunity with a drug cocktail (that will more than likely have better success). Moreover, the AML trial results could be available mid summer of 2014 (this trial could be a sleeper).
In summary, they did not say much about the HDC platform; which lends to the focus on Galaxy 2. I expect to see some analyst upgrades; as this Oncology company has many sponsored trials in Lung, Breast, Ovarian Cancer and AML indications all moving into Phase 2 or 3 trials (and enrolling as we speak). Lastly, the Steifel analyst really digging into Galaxy 1/Galaxy 2 results (this is the same analyst who downgraded the stock down to a $1 (Lets see what he decides to do this time around along with the other analysts as well).